[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexually-transmitted-infections-not-hiv-or-hepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexually-transmitted-infections-not-hiv-or-hepatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100536560","imara-for-black-male-caregivers-and-girls-empowerment-image-100536560",false,"NCT06266416","IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)","A Family-Based HIV Prevention Program for Black Men to Protect Black Girls","IMAGE","Inclusion Criteria:\n\nAIM 1:\n\n* Self-identify as African American, Black, or mixed race with African American or Black\n* Speak English\n* Males must identify as a current caregiver to girl enrolled in the study\n\nAIM 2: All Community Based Organizations (CBO) directors and IMAGE liaisons will be eligible.\n\nExclusion Criteria:\n\nAIM 1:\n\n* Girl refuses to participate\n* Inability to understand the consent\u002Fassent process\n* Non-English speaking\n* Does not self-identify as African American, Black, or mixed race with African American or Black\n* If the primary caregiver (female caregiver\u002Fmother) does not consent to the girls' participation with the male caregiver the girl chooses, the girl will not be able to participate\n* Girls will be excluded if they participated in other phases of the research\n\nAIM 2:\n\n• Inability to understand the consent process, and non-employment at a partnering CBO.",true,"ALL","13 Years",{"count":21,"type":22},612,"ESTIMATED","INTERVENTIONAL",[25],"NA","The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI\u002FHIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI\u002FHIV and sexual violence.",[28,29,30],"Sexually Transmitted Infections (Not HIV or Hepatitis)","HIV Infections","Sexual Behavior",[32,33,34,35],"Sexual Health","HIV Prevention","Community Based","Sexually Transmitted Infections","RECRUITING","2026-04-13",{"date":39,"type":40},"2026-04-17","ACTUAL",{"date":42,"type":40},"2024-09-02",{"date":44,"type":22},"2028-05-31",{"name":46,"class":47},"University of Illinois at Chicago","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100620769","sexual-health-access-at-retail-pharmacies-advancing-pharmacy-based-delivery-of-primary-sti-and-hiv-prevention-for-cisgender-women-100620769","NCT07361926","Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women","SHARP","Inclusion Criteria:\n\n* Cis-gender female\n* Seeking contraception (emergency contraception, oral contraceptive pills, injectables, implants, and condoms) from the retail pharmacy site\n* Age ≥ 15 and \\\u003C25 years old\n* Willingness to receive PrEP screening per national guidelines including HIV testing\n* Not currently taking PrEP\n* Planning to reside in the area for the next 12 months\n* Able and willing to provide informed consent for participation\n\nExclusion Criteria:\n\n* Current participation in other ongoing studies.\n* Medical contraindications to PrEP or doxycycline use (e.g., severe allergy to doxycycline, serious hepatic or renal disease).\n* Any other condition that, in the investigator's judgment, would make participation unsafe or interfere with study procedures.","FEMALE","15 Years","24 Years",{"count":60,"type":22},720,[25],"This proposed 3-arm randomized study will compare different pharmacy based approaches that include HIV prevention medication (PrEP and PEP), routine STI testing, and preventive antibiotic (doxycycline) for STIs. The study will assess how well these services can be implemented, how acceptable they are to young women, and whether they are cost-effective.",[28,29],[65,66,67],"STI prevention","HIV prevention","Pharmacy delivery","NOT_YET_RECRUITING","2026-01-26",{"date":71,"type":40},"2026-01-28",{"date":73,"type":22},"2026-05",{"date":75,"type":22},"2030-06",{"name":77,"class":47},"University of Washington",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":17,"sex":86,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100498535","developing-an-hiv-disclosure-intervention-for-men-in-uganda-100498535","NCT05771519","Developing an HIV Disclosure Intervention for Men in Uganda","Development and Assessment of an HIV Disclosure Intervention for Men in Uganda","DASH","For all 3 Aims, \"index participants\" inclusion criteria will include:\n\n* men living with HIV\n* with sexually transmitted infection symptoms (e.g., urethral discharge, genital lesions)\n* either not accessing antiretroviral therapy (per self-report109 and\u002For clinic documentation) or accessing antiretroviral therapy without HIV viral suppression\n* age ≥18 years,\n* with at least one sexual partner in the past three months\n\nAims 2 and 3 have the additional inclusion criteria:\n\n* men living with HIV without HIV disclosure to at least one partner.\n\nIn Aims 2 and 3, male participants will be encouraged to invite sexual partners for enrollment. These \"partner participants\" will have the following inclusion criteria:\n\n* age ≥18 years\n* partnered with an enrolled man who reports HIV disclosure or plans for HIV disclosure with study support\n* referred by the male participant.\n\nExclusion Criteria:\n\n* an inability to speak the local language (Runyankole) or English\n* an inability to provide informed consent","MALE","18 Years",{"count":89,"type":22},70,[25],"The goal of this clinical trial is to test an HIV disclosure intervention that the investigators are developing focused on men living with HIV in Uganda. The main questions the investigators are trying to answer is whether the HIV disclosure intervention the investigators develop will help men who receive this intervention to disclose their HIV status to a greater extent than men who receive standard care.\n\nParticipants assigned to the intervention group will likely participate in the following:\n\n* Sexual health education\n* Cognitive behavioral therapy strategies\n* Problem-solving skills building\n* Motivational interviewing\n* Developing a personalized HIV disclosure plan\n* Communication skills building\n* Role-playing disclosure strategies",[29,28],"2025-12-08",{"date":95,"type":40},"2025-12-12",{"date":73,"type":22},{"date":98,"type":22},"2027-07",{"name":100,"class":47},"Brigham and Women's Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":17,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100531757","improving-perinatal-outcomes-among-kenyan-pregnant-women-with-an-integrated-sti-testing-model-100531757","NCT06203951","Improving Perinatal Outcomes Among Kenyan Pregnant Women With an Integrated STI Testing Model","PrIMI","Inclusion Criteria:\n\n* Self-identifying as a cisgender woman\n* Seeking antenatal services from the clinic\n* Planning to receive antenatal and postnatal care at the clinic\n* Willingness to receive syndromic STI screening and HIV\u002Fsyphilis testing per national guidelines\n* Able and willing to provide informed consent for participation\n\nExclusion Criteria:\n\n* Male gender\n* Not seeking antenatal services from the clinic\n* Not planning to receive antenatal and postnatal care at the clinic\n* Not willing to receive syndromic STI screening and HIV\u002Fsyphilis testing per national guidelines\n* Not able or willing to provide informed consent for participation",{"count":109,"type":22},3132,[25],"The investigators will conduct a 3-arm individual-level RCT in Kisumu and Siaya, Kenya to compare perinatal outcomes associated with 3 models of STI testing and management in antenatal care. The investigators will enroll 3132 pregnant women and randomize 1:1:1 to receive standard-of-care (syndromic management only without CT, NG, or TV testing) vs. CT, NG, and TV testing using Xpert® assays universally vs. only among women without STI symptoms. All women with STIs detected and\u002For symptoms per Ministry of Health algorithms will receive immediate treatment, EPT per national guidelines, and tests of cure. All participants will be enrolled during routine antenatal care and followed through 9-months postpartum. The investigators will quantify and compare a composite outcome of pregnancy loss\u002Fstillbirth, PTB, LBW, SGA, and neonatal death, between randomization arms, in addition to several secondary and exploratory outcomes.",[113,28],"Hiv","2025-07-10",{"date":116,"type":40},"2025-07-16",{"date":118,"type":40},"2025-01-27",{"date":120,"type":22},"2028-12-31",{"name":77,"class":47},8]